Spots Global Cancer Trial Database for stage iii papillary thyroid cancer

Every month we try and update this database with for stage iii papillary thyroid cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer	NCT00005842	Cancer	trastuzumab tipifarnib	18 Years -	National Cancer Institute (NCI)
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy	NCT00095836	Head and Neck C...	Gefitinib	18 Years -	Massachusetts General Hospital
Iodine I 131 in Treating Patients With Thyroid Cancer	NCT00416949	Head and Neck C...	Patient-specifi...	18 Years - 100 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases	NCT00062348	Colorectal Canc... Head and Neck C... Metastatic Canc...	boronophenylala... sodium borocapt... conventional su...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer	NCT00415233	Head and Neck C...	recombinant thy... Radiodine ablat...	16 Years - 80 Years	University College, London
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer	NCT00005842	Cancer	trastuzumab tipifarnib	18 Years -	National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer	NCT00068497	Anaplastic Thyr... Insular Thyroid... Metastatic Para... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Parat... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Stage III Folli... Stage III Papil... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Verru... Stage IIIB Non-... Stage IV Lympho... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Esthe... Stage IVA Folli... Stage IVA Inver... Stage IVA Lymph... Stage IVA Midli... Stage IVA Mucoe... Stage IVA Papil... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Esthe... Stage IVB Folli... Stage IVB Inver... Stage IVB Lymph... Stage IVB Midli... Stage IVB Mucoe... Stage IVB Papil... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Esthe... Stage IVC Folli... Stage IVC Inver... Stage IVC Lymph... Stage IVC Midli... Stage IVC Mucoe... Stage IVC Papil... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Thryoid Gland N... Thyroid Gland M... Tongue Cancer Untreated Metas...	gefitinib	-	National Cancer Institute (NCI)
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer	NCT00095693	Anaplastic Thyr... Insular Thyroid... Recurrent Thyro... Stage III Folli... Stage III Papil... Stage IV Follic... Stage IV Papill...	sorafenib tosyl... laboratory biom... pharmacological... fludeoxyglucose... positron emissi... dynamic contras...	18 Years -	National Cancer Institute (NCI)
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer	NCT01118065	Head and Neck C...	everolimus	18 Years -	National Cancer Institute (NCI)
Iodine I 131 in Treating Patients With Thyroid Cancer	NCT00416949	Head and Neck C...	Patient-specifi...	18 Years - 100 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy	NCT00095836	Head and Neck C...	Gefitinib	18 Years -	Massachusetts General Hospital
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer	NCT00095693	Anaplastic Thyr... Insular Thyroid... Recurrent Thyro... Stage III Folli... Stage III Papil... Stage IV Follic... Stage IV Papill...	sorafenib tosyl... laboratory biom... pharmacological... fludeoxyglucose... positron emissi... dynamic contras...	18 Years -	National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer	NCT00068497	Anaplastic Thyr... Insular Thyroid... Metastatic Para... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Parat... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Stage III Folli... Stage III Papil... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Verru... Stage IIIB Non-... Stage IV Lympho... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Esthe... Stage IVA Folli... Stage IVA Inver... Stage IVA Lymph... Stage IVA Midli... Stage IVA Mucoe... Stage IVA Papil... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Esthe... Stage IVB Folli... Stage IVB Inver... Stage IVB Lymph... Stage IVB Midli... Stage IVB Mucoe... Stage IVB Papil... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Esthe... Stage IVC Folli... Stage IVC Inver... Stage IVC Lymph... Stage IVC Midli... Stage IVC Mucoe... Stage IVC Papil... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Thryoid Gland N... Thyroid Gland M... Tongue Cancer Untreated Metas...	gefitinib	-	National Cancer Institute (NCI)
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer	NCT01164176	Head and Neck C...	everolimus laboratory biom...	18 Years -	Yonsei University
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer	NCT00415233	Head and Neck C...	recombinant thy... Radiodine ablat...	16 Years - 80 Years	University College, London

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: